江苏省肿瘤医院，是中华人民共和国江苏省的一所医院，为三级甲等医院，位于南京市百子亭42号。

During the past decade, Jiangsu Cancer Hospital conducted 143 clinical trials. In the 10-year time frame, 143 clinical trials started and 39 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 54 clinical trials started and 28 clinical trials were completed. i.e. 51.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jiangsu Cancer Hospital" #1 sponsor was "Hoffmann-La Roche" with 30 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 13 trials sponsored, "Jiangsu Cancer Institute & Hospital" with 10 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 8 trials sponsored and "Betta Pharmaceuticals Co., Ltd." with 8 trials sponsored. Other sponsors include 104 different institutions and companies that sponsored additional 70 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jiangsu Cancer Hospital" #1 collaborator was "LinkDoc Technology (Beijing) Co. Ltd." with 9 trials as a collaborator, "Jiangsu Cancer Institute & Hospital" with 3 trials as a collaborator, "Eisai Inc." with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Tigermed Consulting Co., Ltd" with 2 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Jiangsu Cancer Hospital" are "Non-small Cell Lung Cancer" (12 trials), "Breast Cancer" (11 trials), "Gastric Cancer" (7 trials), "Esophageal Squamous Cell Carcinoma" (6 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Jiangsu Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Jiangsu Cancer Hospital" are "Drug" (155 trials), "Biological" (13 trials), "Procedure" (12 trials), "Other" (10 trials) and "Radiation" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (36 trials), "Cisplatin" (12 trials), "Atezolizumab" (11 trials), "Docetaxel" (10 trials) and "Anlotinib" (9 trials). Other intervention names were less common.

The vast majority of trials in "Jiangsu Cancer Hospital" are 155 trials for "All" genders, 12 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are 72 active trials in "Jiangsu Cancer Hospital". 3 are not yet recruiting, 41 are recruiting, 27 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 64 completed trials in Jiangsu Cancer Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Jiangsu Cancer Hospital, 21 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 100 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".